HC Wainwright & Co. Maintains Buy on MoonLake, Lowers Price Target to $26

MoonLake Immunotherapeutics - Class A Ordinary Shares -0.63% Pre

MoonLake Immunotherapeutics - Class A Ordinary Shares

MLTX

14.90

14.95

-0.63%

+0.34% Pre
HC Wainwright & Co. analyst Raghuram Selvaraju maintains MoonLake (NASDAQ: MLTX) with a Buy and lowers the price target from $30 to $26.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via